Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Czech Republic caps fuel prices amid Iran war energy crisis- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
- Manual for Instructive Application for Youngsters
- Can ICE agents detain U.S. citizens? What powers do they have to arrest people? Your most common questions answered.
- US bishops officially ban gender-affirming care at Catholic hospitals
- 7 Odd Apparatuses to Make Your Party Stick Out!
- Figure out How to Involve a Brain science Certification in Showcasing
- Kendall Jenner addresses long-standing rumor about her sexuality
- German foreign minister heads to China to talk rare-earth exports
